Volume | 170,248 |
|
|||||
News | - | ||||||
Day High | 0.3599 | Low High |
|||||
Day Low | 0.3227 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Trevena Inc | TRVN | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.347 | 0.3227 | 0.3599 | 0.352 | 0.366 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
426 | 170,248 | $ 0.3451503 | $ 58,761 | - | 0.3227 - 3.28 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
17:15:36 | formt | 134 | $ 0.3549 | USD |
Trevena Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
6.41M | 18.32M | - | 3.13M | -40.29M | -2.20 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Trevena News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical TRVN Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.419 | 0.43 | 0.3227 | 0.3923048 | 1,017,174 | -0.0641 | -15.30% |
1 Month | 0.509 | 0.51 | 0.3227 | 0.399087 | 382,916 | -0.1541 | -30.28% |
3 Months | 0.6383 | 0.70 | 0.3227 | 0.4693645 | 206,579 | -0.2834 | -44.40% |
6 Months | 0.6095 | 0.7693 | 0.3227 | 0.5356381 | 160,994 | -0.2546 | -41.77% |
1 Year | 0.7301 | 3.28 | 0.3227 | 1.96 | 999,247 | -0.3752 | -51.39% |
3 Years | 45.375 | 55.00 | 0.3227 | 17.66 | 1,165,930 | -45.02 | -99.22% |
5 Years | 37.00 | 112.50 | 0.3227 | 40.13 | 1,940,454 | -36.65 | -99.04% |
Trevena Description
Trevena Inc is an American biotechnology company. The portfolio pipeline is focused on medicines targeting pain management: TRV734: oral medicine for moderate to severe pain; TRV250: oral medicine for migraines; and TRV027: treatment for acute heart failure. Its leading product is oliceridine (TRV130), a protein-based chemical meant to manage moderate to severe acute pain. |